IMR Press / RCM / Volume 20 / Issue 1 / DOI: 10.31083/j.rcm.2019.01.51
Open Access Review
Renal nerve ablation for resistant hypertension: facts, fictions and future directions
Show Less
1 CNR Institute of Clinical Physiology, c/o EUROLINE, Via Vallone Petrara 55-57, 89124 Reggio Calabria, Italy
2 Renal Unit, Department of Health Sciences, "Magna Graecia" University, 88100 Catanzaro, Italy
Rev. Cardiovasc. Med. 2019, 20(1), 9–18;
Published: 30 March 2019

Hypertension remains a major public health problem and one of the most relevant causes of cardiovascular mortality and morbidity worldwide. Roughly 10% of hypertensive individuals are considered as “resistant” as they are not able to achieve and maintain optimal blood pressure values despite the concurrent use of 3 antihypertensive agents of different classes at optimal doses. As resistant hypertension conveys a higher risk of adverse outcomes, the search for effective treatments to properly manage this condition has progressively surged as a true health priority. The renal nerve plexus plays a central role in regulating arterial blood pressure and renal sympathetic overactivity is a major component in the development and progression of hypertension. On these premises, minimally-invasive catheter based devices for renal nerve ablation have been developed and tested as an alternative treatment for resistant hypertension, but clinical study results have been ambiguous. This review provides a historical perspective on the scientific evidence forming the foundation of renal never ablation from accrued clinical evidence to possible future applications, reaching a tentative conclusion that more research and clinical experience is needed to fully reveal limits and potential indications of this procedure.

Resistant hypertension
renal denervation
renal nerve ablation
Figure 1.
Back to top